Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Non Operating Income (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Non Operating Income readings, the most recent being $6.2 million for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 81.64% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.7 million, a 105.39% decrease, with the full-year FY2025 number at -$5.2 million, down 115.43% from a year prior.
  • Non Operating Income hit $6.2 million in Q4 2025 for Avalo Therapeutics, up from -$11.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $88.5 million in Q2 2024 to a low of -$88.5 million in Q1 2024.
  • Median Non Operating Income over the past 5 years was -$1.0 million (2021), compared with a mean of $3.0 million.
  • Biggest five-year swings in Non Operating Income: crashed 10863.64% in 2021 and later skyrocketed 2541.09% in 2024.
  • Avalo Therapeutics' Non Operating Income stood at -$1.2 million in 2021, then plummeted by 252.2% to -$4.2 million in 2022, then increased by 0.79% to -$4.1 million in 2023, then surged by 909.81% to $33.5 million in 2024, then plummeted by 81.64% to $6.2 million in 2025.
  • The last three reported values for Non Operating Income were $6.2 million (Q4 2025), -$11.4 million (Q3 2025), and -$5000.0 (Q2 2025) per Business Quant data.